# BPC Research



### **Metal Hawk Limited**

### Non-Energy Minerals – Ni, Au MHK A\$0.155


Metal Hawk Limited (MHK) is a Western Australian mineral exploration company focused on early-stage discovery of gold and nickel sulphides. Metal Hawk owns a number of quality projects in the Eastern Goldfields and the Albany Fraser regions. Since RC drilling commenced in September 2021, Metal Hawk has discovered high grade nickel sulphide and gold mineralisation at the Berehaven Project, located 20km southeast of Kalgoorlie. The Company has consolidated over 90km2 of underexplored tenure at Berehaven, which is situated north of the Blair Nickel sulphide deposit.

### Company Data

Number of shares	58.2M
Market Capitalisation (\$m)	9.0
Free float (%)	N/A
12-month high/low	\$0.76/\$0.145
Average Daily Turnover (\$m)	0.01
% S&P/ASX200	0.000%
DDM Ranking	N/A
% All Ordinaries	0.000%
GICS Industry Group	Mining
Source: FactSet, BPC	

### **Mineral Resource**

N/A



## IGO COMMITS TO STAGE-2 OF NICKEL JOINT VENTURE

On  $23^{rd}$  of June 2022, Metal Hawk Limited (MHK) announced an update to its JV Projects with IGO Limited (ASX : IGO), with the following highlights:

### Highlights:

- IGO, through its wholly owned subsidiary, Western Areas Limited, has satisfied the Stage-1 requirements of its Earn-In and Joint Venture Agreement (EIJVA) with Metal Hawk, having spent \$3M on exploration across the Joint Venture Projects;
- IGO achieved the Stage-1 milestone well ahead of the required timeframe and is now entitled to a 51% joint venture interest in Metal Hawk's Kanowna East, Emu Lake and Fraser South projects;
- IGO elects proceed to Stage-2 with a further \$4.0m expenditure required to earn an additional 24% interest;
- Metal Hawk is free-carried to a decision to mine and retains 100% of the gold rights at Kanowna East and Emu Lake;
- Exploration activity significantly ramping up across all JV projects during Q3-Q4 2022;

### **MD comments:**

MHK MD, Will Belbin, commented: "We have been really pleased with the pace and quality of exploration carried out by our joint venture partner, which has exceeded its obligation under the earnin agreement, and with the results achieved to date. The election by IGO to progress to Stage-2 is a tremendous outcome for Metal Hawk that will see a substantial step-up in exploration expenditure without drawing on shareholders' funds. We also see this as a strong endorsement of the quality and potential of these projects."

### **BPC comments:**

• IGO has elected to progress to Stage-2 of Nickel JV with MHK. Exploration activity will significantly ramp up across all JV projects during the second half 2022.

### Russell Wright


23 June 2022 russell@barclaypearce.com.au Barclay Pearce Capital Management Level 17, 115 Pitt St Sydney NSW 2000 www.barclaypearce.com.au

## BPC RESEARCH



Appendix A.

### **Metal Hawk project locations**



Russell Wright 23 June 2022 russell@barclaypearce.com.au

Barclay Pearce Capital Management Level 17, 115 Pitt St Sydney NSW 2000 www.barclaypearce.com.au

# BPC Research



#### Disclaimer

This Research Report has been prepared by Russell Wright ("Mr Wright") in his capacity as an Authorised Representative (AR: 422117) and is issued by Barclay Pearce Capital Management Pty Ltd (BPCM) AFSL 503261.

This Research is intended solely for the information of the particular person to whom it was provided by BPCM and should not be relied upon by any other person. The information in this Research does not purport to be complete nor does it contain all the information which a prospective investor may require. The information contained in this Research is general in nature and does not constitute advice nor a recommendation to deal. This Research does not constitute specific advice and does not take into account financial objectives or situation of an investor. All and any recipients of this Research acknowledge and agree that they must conduct and have conducted their own due diligence investigation and have not relied upon any representations of BPCM, its officers, employees, representatives or associates. BPCM has not independently verified the information contained in this Research. BPCM assumes no responsibility for updating any information, views or opinions contained in this Research or for correcting any error or omission which may become apparent after the Research has been issued. BPCM does not give any warranty as to the accuracy, reliability or completeness of advice or information which is contained in this Research. Except insofar as liability under any statute cannot be excluded, BPCM and its officers, employees, representatives or associates do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this Research or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this Research or any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party. This Research must not be distributed or released in the United States. It may only be provided to persons who are outside the United States and are not, and are not acting for the account or benefit of, "US Persons" in connection with transactions that would be "offshore transactions" (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). Any securities mentioned in the Research have not been and will not be registered under the Securities Act or the securities laws of any state or jurisdiction of the United States, and may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws in the United States or to, or for the account or benefit of, a US Person. This Research does not, and is not intended to, constitute an offer or invitation in the United States, or in any other place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation. If you are not the intended recipient of this Research, please notify BPCM immediately and destroy all copies of this Research, whether held in electronic or printed form or otherwise.

#### **Disclosure of Interest**

The Company, its officers, employees, representatives and associates within the meaning of Chapter 7 of the Corporations Act may receive commissions and management fees from transactions involving securities referred to in this Research (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this Research. The Company does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

#### **Analyst Certification**

The research analyst(s) identified above individually certify that in respect of each security or issuer that the research analyst covers that: this report accurately reflects his or her personal views about any and all of the subject issuer(s) or securities; and no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by the research analyst(s) in this report. BPCM provides research services to its client. Mr Wright is General Manager of Research and has over thirty (30) years' experience in the financial services industry, particularly in financial analysis and research report writing. Mr Wright joined the BPCM team in 2021 where he has been involved in the research and publication of reports. Prior to this Mr Wright worked at a number of entities where he held Director/Head of Research and General Manager of Research positions. Mr Wright holds a Bachelor of Mathematics (Honours) from Edinburgh University and has completed the SDIA Accreditation Program (RG146) through DeakinPrime.

#### **Conflicts of Interest**

BPCM does have material interests in the financial product discussed in this Research Report and it will receive benefits in relation to the publication of this Research Report. BPCM manages all Conflicts of Interest in accordance with its Conflicts of Interest Policy. Please contact us if you require any further information.

### **Meanings of Barclay Pearce Capital Stock Ratings**

Buy – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of 15% or more within a 12-month period.

Hold - Describes stocks that are neither a buy nor underperform.

Underperform – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of less than minus 10% within a 12-month period.

**Speculative Buy** – Describes stocks we research with a positive bias, whose company fundamentals and/or financials are being covered, but for which there is insufficient information for BPCM to assign a Buy or Underperform rating.

### **Russell Wright**

23 June 2022 russell@barclaypearce.com.au Barclay Pearce Capital Management Level 17, 115 Pitt St Sydney NSW 2000 www.barclaypearce.com.au

# BPC RESEARCH



### **Valuation Methodology**

BPCM's methodology for assigning stock and credit ratings may include the following: market capitalisation, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of peer comparisons, market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of parts, net asset value, discounted dividend model (DDM), franking credits and return on equity (ROE) over the next 12 months.

### **Barclay Pearce Capital Recommendation Proportions**

Buy	37.9%	0.0% of stocks with recommendations are Barclay Pearce clients)
Hold	22.8%	0.0% of stocks with recommendations are Barclay Pearce clients)
Underperform	39.4%	0.0% of stocks with recommendations are Barclay Pearce clients)

Russell Wright 23 June 2022 russell@barclaypearce.com.au

Barclay Pearce Capital Management Level 17, 115 Pitt St Sydney NSW 2000 www.barclaypearce.com.au